Sensei Biotherapeutics (SNSE) Competitors $8.68 +1.18 (+15.73%) Closing price 08/15/2025 03:58 PM EasternExtended Trading$8.03 -0.65 (-7.49%) As of 08/15/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SNSE vs. CALC, PLUR, JSPR, OVID, STTK, ALXO, FGEN, PEPG, XLO, and KPTIShould you be buying Sensei Biotherapeutics stock or one of its competitors? The main competitors of Sensei Biotherapeutics include CalciMedica (CALC), Pluri (PLUR), Jasper Therapeutics (JSPR), Ovid Therapeutics (OVID), Shattuck Labs (STTK), ALX Oncology (ALXO), FibroGen (FGEN), PepGen (PEPG), Xilio Therapeutics (XLO), and Karyopharm Therapeutics (KPTI). These companies are all part of the "pharmaceutical products" industry. Sensei Biotherapeutics vs. Its Competitors CalciMedica Pluri Jasper Therapeutics Ovid Therapeutics Shattuck Labs ALX Oncology FibroGen PepGen Xilio Therapeutics Karyopharm Therapeutics CalciMedica (NASDAQ:CALC) and Sensei Biotherapeutics (NASDAQ:SNSE) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, media sentiment, profitability and risk. Is CALC or SNSE more profitable? Sensei Biotherapeutics' return on equity of -72.13% beat CalciMedica's return on equity.Company Net Margins Return on Equity Return on Assets CalciMedicaN/A -206.51% -103.81% Sensei Biotherapeutics N/A -72.13%-61.35% Do analysts prefer CALC or SNSE? CalciMedica currently has a consensus target price of $16.00, indicating a potential upside of 449.83%. Sensei Biotherapeutics has a consensus target price of $55.00, indicating a potential upside of 533.64%. Given Sensei Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Sensei Biotherapeutics is more favorable than CalciMedica.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CalciMedica 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Sensei Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Which has more volatility & risk, CALC or SNSE? CalciMedica has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500. Comparatively, Sensei Biotherapeutics has a beta of 0.26, meaning that its stock price is 74% less volatile than the S&P 500. Does the media refer more to CALC or SNSE? In the previous week, CalciMedica had 6 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 10 mentions for CalciMedica and 4 mentions for Sensei Biotherapeutics. Sensei Biotherapeutics' average media sentiment score of 0.47 beat CalciMedica's score of 0.08 indicating that Sensei Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CalciMedica 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sensei Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals believe in CALC or SNSE? 10.5% of Sensei Biotherapeutics shares are owned by institutional investors. 41.6% of CalciMedica shares are owned by insiders. Comparatively, 23.2% of Sensei Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has stronger earnings & valuation, CALC or SNSE? CalciMedica is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCalciMedicaN/AN/A-$13.70M-$1.60-1.82Sensei BiotherapeuticsN/AN/A-$30.16M-$21.31-0.41 SummarySensei Biotherapeutics beats CalciMedica on 9 of the 14 factors compared between the two stocks. Get Sensei Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SNSE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNSE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNSE vs. The Competition Export to ExcelMetricSensei BiotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.95M$3.14B$5.72B$9.79BDividend YieldN/A2.22%3.91%4.13%P/E Ratio-0.4121.0331.1425.06Price / SalesN/A285.40416.7890.80Price / CashN/A42.6136.7858.67Price / Book0.408.659.086.18Net Income-$30.16M-$54.65M$3.26B$265.11M7 Day Performance15.72%6.56%7.39%4.22%1 Month Performance8.23%4.82%4.22%0.77%1 Year Performance-29.43%15.81%30.30%24.69% Sensei Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNSESensei Biotherapeutics4.5408 of 5 stars$8.68+15.7%$55.00+533.6%-29.4%$10.95MN/A-0.4140News CoverageCALCCalciMedica3.3458 of 5 stars$2.76+0.7%$16.00+479.7%-30.5%$38.28MN/A-1.7730Earnings ReportShort Interest ↓Analyst RevisionGap UpPLURPluri2.2449 of 5 stars$4.55-5.6%$12.00+163.7%-11.4%$37.91M$330K-0.82150Short Interest ↑JSPRJasper Therapeutics2.962 of 5 stars$2.63+7.3%$29.75+1,031.2%-82.8%$36.80MN/A-0.5020News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionOVIDOvid Therapeutics4.2249 of 5 stars$0.56+7.9%$3.10+457.9%-14.2%$36.61M$570K-1.5960News CoverageEarnings ReportAnalyst UpgradeShort Interest ↑Analyst RevisionGap UpSTTKShattuck Labs3.5413 of 5 stars$0.74-2.3%$7.50+914.6%-70.2%$36.23M$5.72M-0.53100News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionGap UpALXOALX Oncology2.9103 of 5 stars$0.61-9.2%$3.30+437.0%-74.6%$36.14MN/A-0.2540Earnings ReportGap DownFGENFibroGen4.5863 of 5 stars$8.37-3.9%$43.00+413.7%+3.9%$35.20M$29.62M-3.35570News CoverageEarnings ReportAnalyst DowngradeAnalyst RevisionHigh Trading VolumePEPGPepGen3.3733 of 5 stars$1.01-5.6%$7.67+659.1%-86.3%$35.10MN/A-0.3430Gap UpXLOXilio Therapeutics2.7955 of 5 stars$0.68+2.6%$3.00+341.0%-18.0%$34.33M$6.34M-0.8170News CoverageEarnings ReportAnalyst DowngradeAnalyst RevisionHigh Trading VolumeKPTIKaryopharm Therapeutics3.8584 of 5 stars$3.77-4.3%$37.40+892.0%-51.8%$34.04M$145.24M-0.28380Earnings ReportAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies CALC Alternatives PLUR Alternatives JSPR Alternatives OVID Alternatives STTK Alternatives ALXO Alternatives FGEN Alternatives PEPG Alternatives XLO Alternatives KPTI Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNSE) was last updated on 8/17/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredNew Federal Land Rush About to Start?A $100 Trillion Wealth Shift Is Already Underway Lithium. Oil. Gold. Trillions in U.S. resources are being ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sensei Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sensei Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access